Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
Are there any situations where you would use Temodar alone without radiation in a patient with oligodendroglioma, WHO grade II, IDH mutant, 1P/19Q codeleted who is unresectable?
Related Questions
What is your approach to management of a subtotally resected pineal parenchymal tumor of intermediate differentiation (CNS WHO grade 2)?
What systemic therapy options are preferred in a patient with recurrent glioblastoma with leptomeningeal dissemination?
Do you refer all patients with new findings of CNS or epidural disease to ED for evaluation or are there some that can be managed completely outpatient?
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
How do you use Boswellia for radiation necrosis?
How would you approach a patient over the age of 40 with a sub-totally resected frontal oligodendroglioma, WHO Grade II, 1p/19q co-deleted, IDH mutant, with imaging concerning for second site in the pontomedullary junction?
Is it reasonable to extrapolate data from Glioblastoma and discuss Tumor Treating Fields in patients with Grade 4, IDH Mutant, astrocytomas?
How do you approach treatment of sub-total resected ZFTA fusion ependymoma after radiation therapy in a young adult?
Are there discernible alterations in sleep patterns following local treatment for pineal gland tumors?
If memantine were started 6 weeks after completion of radiation to base of skull, would you expect any potential benefit?
